Laser Therapy for Hair Loss: What the Evidence Actually Shows

In short: yes, home laser devices for hair loss have been tested in randomised, double-blind, sham-controlled trials, and a meta-analysis pooling eleven of them found a significant increase in hair density (SMD 1.316, 95% CI 0.993–1.639; PubMed 30706177). But that is exactly half the picture, and the other half appears on no product page: the broadest comparative analysis of six non-surgical treatments did rank low-level laser therapy first on effect size — and in the same abstract graded the quality of the evidence behind the laser-versus-sham comparison as "very low", the bottom of the scale, while grading comparisons between minoxidil concentrations as "high" (PubMed 29797431). The high ranking rests on weak evidence, not strong evidence. Practically: there is probably a real effect, its size is genuinely uncertain, almost all of the trials were funded by the device manufacturers, and the cleared US indication covers only Norwood-Hamilton IIa to V and specifies use three times a week for at least 26 weeks.

A laser cap costs several thousand shekels in Israel. It is sold in pharmacy chains and on price-comparison sites, and it is marketed as a way to avoid seeing a doctor. Search in English for whether laser caps work and you land on one of two things: a page written by someone selling the device, or a page written by a transplant clinic that has no commercial interest in the device working.

There is a third answer. It is neither yes nor no, it lives in the published literature, and it is more interesting than either.

What is laser therapy for hair loss?

The technical term is low-level laser therapy (LLLT), also called photobiomodulation. It uses red or near-infrared light, typically around 650 to 680 nanometres, at an intensity too low to heat or damage tissue. Home devices come in three broad shapes: a comb passed over the scalp, a cap or helmet worn on the head, and panel arrays positioned above the scalp.

The proposed mechanism is that the light is absorbed by mitochondria in follicular cells and alters cellular energy production, pushing follicles into the growth phase earlier than they otherwise would. It is worth being precise about what that is: a mechanistic hypothesis. It is not the same question as whether the device works clinically, and it was not directly tested in most of the clinical trials.

What did the controlled trials find?

Unlike several other things sold for hair loss, there is real material here. Laser devices have been tested in randomised, double-blind, sham-controlled trials — quite a few of them.

• The largest randomised programme enrolled 128 men and 141 women, randomised to receive either a laser comb or a sham device across four parallel controlled trials. Devices were dispensed in concealed, sealed, identical packets; site investigators and subjects remained blinded throughout; and the evaluator of the masked photographs was blinded to trial arm. Treatment was three times a week for 26 weeks (PubMed 24474647).
• A systematic review pooled 11 studies covering 680 patients — 444 men and 236 women. Nine of the 11 studies assessing hair count or density found statistically significant improvement. Patient satisfaction, examined in five studies, was positive overall but, in the authors' words, less pronounced than the objective outcomes (PubMed 27114071).
• A quantitative meta-analysis of eight papers comprising 11 double-blind randomised controlled trials found a significant increase in hair density for laser versus sham, with a standardised mean difference of 1.316 (95% CI 0.993 to 1.639). The effect appeared in both sexes and with both comb-type and helmet-type devices (PubMed 30706177).
• A 24-week randomised, double-blind, sham-device-controlled trial in 40 subjects, 20 of them men, found the laser helmet significantly superior to sham for hair density (p = 0.002) and hair diameter (p = 0.009) (PubMed 30569416).

So far the picture looks good. A reader who stops here — and stopping here is exactly what product pages are designed to make you do — comes away thinking this is a well-established treatment.

If laser ranked first, why isn't that the end of it?

In 2018 the Journal of the European Academy of Dermatology and Venereology published a systematic review and network meta-analysis — a method that allows treatments never tested head-to-head to be compared indirectly. It examined six non-surgical treatments for androgenetic alopecia: dutasteride, finasteride, low-level laser therapy, minoxidil at two concentrations, and PRP. Seventy-eight studies met the inclusion criteria and 22 provided data sufficient for the network analysis (PubMed 29797431).

The sentence from that paper quoted everywhere is that relative effects show LLLT as the superior treatment. That is accurate. The sentence quoted nowhere appears in the same abstract, a few lines later, and grades the evidence itself:

Comparison	Quality of evidence
Minoxidil 2% vs minoxidil 5%	High
Minoxidil 5% vs placebo	Moderate
Dutasteride (male) vs placebo	Low
Minoxidil 2% vs placebo	Low
Minoxidil 5% vs LLLT	Low
Finasteride (male) vs placebo	Very low
LLLT vs sham	Very low
PRP vs placebo	Very low

Source: PubMed 29797431. What this table says, and what it does not: the grade describes how certain we can be about the comparison itself — how many trials, of what quality, with what risk of bias — not whether a treatment works. "Very low certainty" does not mean "does not work". It means the estimate could change substantially once better trials exist.

This is the point of the page. The very paper that produced the laser's high ranking grades the evidential basis for that ranking at the lowest available level. The gap between "ranked first" and "very low certainty" is the whole story, and it is systematically deleted from every page that sells the device.

Why is it so hard to run a good laser trial?

Three reasons, all of them raised explicitly by the investigators themselves.

First, blinding. In a drug trial you can make a placebo pill that is genuinely indistinguishable. A laser device emits visible light, warms slightly, and makes a sound. The investigators on the 24-week helmet trial listed this among their own limitations: the use of inappropriate sham devices, which do not reflect a true negative control (PubMed 30569416). A participant who can see that his device does not light up knows which arm he is in, and that leaks into subjective outcomes and self-reported shedding.

Second, funding. The 2018 systematic review and meta-analysis concluded that the devices did stimulate hair growth relative to sham, but that the results must be interpreted with caution, and that further studies with larger samples, longer follow-up and — stated explicitly — independent funding sources are necessary (PubMed 29286826). Nearly all of the existing evidence comes from trials funded by the people selling the device.

Third, duration. The trials run 16 to 26 weeks. Male pattern hair loss is a chronic, progressive condition measured in decades. There are no long-term follow-up data showing what happens at two years or five, and none showing what happens when use stops.

What did the regulators actually clear?

There is a distinction here worth knowing, because marketing copy blurs it. Laser hair devices sit in the FDA device database under product code OAP, "Laser, Comb, Hair", as a Class II device under regulation 890.5500. The route to market is 510(k).

A 510(k) is a substantial-equivalence submission: the manufacturer demonstrates that its device is sufficiently similar to one already legally marketed. It is not the approval pathway that requires each product to independently demonstrate clinical benefit. "FDA cleared" and "FDA approved" are not the same thing, and most product pages use the second phrase.

The second detail almost never carried into marketing is the indication itself. The classification defines the device as intended to promote hair growth in males with androgenic alopecia and Norwood-Hamilton classification of IIa to V, and describes the technical method as passing the device across the scalp three times a week for at least 26 weeks. A man whose loss is more extensive than Norwood V is outside the indication that was studied, and a man expecting a result in a month or two is expecting something no trial measured.

Who is this reasonable for, and who not?

A practical answer follows from the above, without substituting for a clinician's judgement.

A device is more likely to be relevant for someone whose loss falls inside the studied range — early to moderate, not complete baldness; who can realistically commit to three sessions a week for at least six months before judging the result; and who understands that he is buying a low-certainty adjunct, not a substitute for assessment.

It is less relevant for someone looking for a single fast fix; for someone whose shedding began abruptly or comes with other symptoms, which is a situation calling for a workup rather than a device; and for someone on a limited budget choosing between a device and a clinical assessment. In that last case the assessment comes first, because it is what establishes whether this is androgenetic alopecia at all.

As for "laser or medication": the analysis above did not find laser to be reliably superior. It found a higher point estimate carrying far lower certainty. The direct minoxidil 5% versus LLLT comparison was graded low certainty — meaning there is no firm basis for declaring a winner. Anyone presenting that question as settled is selling you a confidence the literature does not supply. Our overview of treatments for hair loss and our comparison of PRP against medical treatment go through the same evidence-quality question for other options.

Frequently asked questions

Does a laser cap actually grow hair?

Randomised, double-blind, sham-controlled trials found a significant increase in hair density, and a meta-analysis of eleven such trials found a standardised mean difference of 1.316 (PubMed 30706177). That said, the broadest network meta-analysis in the field graded the quality of evidence for laser versus sham as "very low" (PubMed 29797431), and most trials were funded by device manufacturers. The honest answer is: probably yes, by an amount that is genuinely uncertain.

How long do I need to use a laser device before judging it?

The technical method recorded in the FDA device classification is three times a week for at least 26 weeks, which is also the duration of the largest randomised programme (PubMed 24474647). Other trials ran 16 to 24 weeks. Judging the result after a month or two is not based on any published data.

Laser or medication — which is better?

There is no evidence-based answer. In the same network meta-analysis, the direct minoxidil 5% versus LLLT comparison was graded low certainty and the LLLT versus sham comparison very low, while the comparison between the two minoxidil concentrations was graded high (PubMed 29797431). Which treatment is appropriate is a clinical decision made by a physician based on your situation, not by an internet ranking.

Can laser be combined with medical treatment?

Combinations are common in practice, but the direct evidence for the combination is considerably thinner than the evidence for either component alone. If you are already on a treatment prescribed by a clinician, tell them before adding a device — not because of an interaction risk, but so that any change in your condition can be interpreted correctly.

Does laser therapy for hair have side effects?

The reported safety profile in trials was good, and reviews describe the devices as safe for self-administration in the home setting (PubMed 29286826). The 24-week helmet trial reported temporary hair shedding and scalp pruritus (PubMed 30569416). These are short, small studies, so long-term safety data are limited.

How do I know whether a specific device was actually tested?

Most devices on sale were not. The evidence that exists attaches to specific models tested in specific trials; it does not transfer automatically to every product that emits red light. It is reasonable to ask a seller for the trial that tested that model, and to check whether the manufacturer funded it — reviews in this area flag funding as a central limitation.

The bottom line

Home laser therapy for hair loss is neither a scam nor a shortcut. It has been tested in randomised double-blind trials, it did increase hair density relative to sham devices, and it was ranked first on effect size in the broadest comparison performed. But that same comparison grades the certainty behind the ranking at the lowest available level; the investigators state plainly that independently funded trials are needed; the sham devices are not a true control; and the studied indication is limited to Norwood-Hamilton IIa to V with at least 26 weeks of use. Someone who buys a device understanding all that is buying a reasonable adjunct. Someone who buys it instead of getting assessed has skipped the step that establishes whether this is androgenetic alopecia in the first place.

Medical disclaimer: this page provides general medical information and is not personal medical advice, a diagnosis, or a treatment recommendation. Whether a treatment is appropriate is determined by a physician based on your circumstances. Do not start, change or stop any treatment on the basis of this page. This page is not a recommendation to purchase any device and has no commercial relationship with any device manufacturer.

Sources: Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. J Eur Acad Dermatol Venereol. 2018 — PubMed 29797431 · Liu KH et al. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a systematic review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2019 — PubMed 30706177 · Delaney SW et al. Systematic review of low-level laser therapy for adult androgenic alopecia. J Cosmet Laser Ther. 2018 — PubMed 29286826 · Jimenez JJ et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014 — PubMed 24474647 · Suchonwanit P et al. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019 — PubMed 30569416 · Afifi L et al. Low-level laser therapy as a treatment for androgenetic alopecia. Lasers Surg Med. 2017 — PubMed 27114071 · FDA device classification, product code OAP (Laser, Comb, Hair), 21 CFR 890.5500